Dalbavancin for prosthetic joint infections: Empirical treatment

被引：0

作者：

Mairesse, R. ^{[1
]}

Gautie, L. ^{[1
]}

Merouani, M. ^{[3
]}

Bouige, A. ^{[1
]}

Fourcade, C. ^{[1
]}

Krin, G. ^{[1
]}

Marlin, P. ^{[1
]}

Giordano, G. ^{[1
]}

Baklouti, S. ^{[2
]}

Gandia, P. ^{[2
]}

Bonnet, E. ^{[1
]}

机构：

[1] Hop Joseph Ducuing, 15 Rue Varsovie, F-31000 Toulouse, France

[2] CHU Toulouse, Rue Viguerie, F-31000 Toulouse, France

[3] Clin Medipole, Rue Geronis, F-31000 Toulouse, France

来源：

INFECTIOUS DISEASES NOW | 2025年 / 55卷 / 02期

关键词：

Antibiotic; Dalbavancin; Efficiency; Prosthetic Joint Infection; Safety; BONE; PREDICTORS; SKIN;

D O I：

10.1016/j.idnow.2025.105035

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: Bone and joint infections are complex and require a long course of antibiotics. Dalbavancin is a long half-life lipoglycopeptide, only indicated for skin and soft tissue infections. Studies on bone and joint diffusion are promising. The objective of this study was to evaluate the efficacy and safety of dalbavancin in combination with piperacillin-tazobactam for intra-operative treatment of knee or hip prosthetic joint infections. Patients and methods: This retrospective and bicentric study was conducted between 2018 and 2022 and included 56 patients. The criteria used to diagnose prosthetic joint infections were those established in 2011 by the MusculoSkeletal Infection Society (MSIS), modified in 2013 at the International Consensus Meeting on Periprosthetic Joint Infections. The efficacy endpoint was the absence of relapse during the two-year follow-up period. Results: Gram-positive cocci infections were the most common. All Gram-positive bacteria were susceptible to dalbavancin. The cure rate at two years was 91.5%. Only four patients experienced treatment failure. Few adverse events were reported, mainly digestive ones (diarrhea and pain). Conclusion: This study provides data outside of the marketing authorization, while respecting the authorized dosage in a population of patients with clearly defined inclusion criteria and a two-year follow-up.

引用

页数：6

共 29 条

[1] Jones R.N., Sader H.S., Flamm R.K., Update of dalbavancin spectrum and potency in the USA: report from the SENTRY antimicrobial surveillance program (2011), Diagn Microbiol Infect Dis, 75, 3, pp. 304-307, (2013)
[2] Puhto A.P., Puhto T., Niinimaki T., Ohtonen P., Leppilahti J., Syrjala H., Predictors of treatment outcome in prosthetic joint infections treated with prosthesis retention, Int Ortho (SICOT), 39, 9, pp. 1785-1791, (2015)
[3] Peel T.N., Cheng A.C., Choong P.F.M., Buising K.L., Early onset prosthetic hip and knee joint infection: treatment and outcomes in Victoria, Australia J Hospital Infection, 82, 4, pp. 248-253, (2012)
[4] Solon E.G., Dowell J.A., Lee J., King S.P., Damle B.D., Distribution of radioactivity in bone and related structures following administration of [ <sup>14</sup> C]dalbavancin to New Zealand white rabbits, Antimicrob Agents Chemother, 51, 8, pp. 3008-3010, (2007)
[5] Pfaller M.A., Flamm R.K., Castanheira M., Sader H.S., Mendes R.E., Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016), Int J Antimicrob Agents, 51, 4, pp. 608-611, (2018)
[6] Dunne M.W., Puttagunta S., Sprenger C.R., Rubino C., Van Wart S., Baldassarre J., Extended-duration dosing and distribution of dalbavancin into bone and articular tissue, Antimicrob Agents Chemother, 59, 4, pp. 1849-1855, (2015)
[7] Senneville E., Joulie D., Legout L., Valette M., Dezeque H., Beltrand E., Et al., Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to staphylococcus aureus, Clin Infect Dis, 53, 4, pp. 334-340, (2011)
[8] Rimmele T., Diffusion of levofloxacin into bone and synovial tissues, J Antimicrob Chemother, 53, 3, pp. 533-535, (2004)
[9] Chen A.F., Heller S., Parvizi J., Prosthetic joint infections, Surg Clin N Am, 94, 6, pp. 1265-1281, (2014)
[10] Orgn S., Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis), Médecine et Maladies Infectieuses, 40, 4, pp. 185-211, (2010)

← 1 2 3 →